TL;DR
Researchers have developed a highly selective CDK9 inhibitor, i-CDK9, that unexpectedly boosts MYC expression in cancer cells. This MYC induction is a compensatory mechanism that allows cells to survive CDK9 inhibition, suggesting that a combined therapy targeting both CDK9 and MYC is needed for effective cancer treatment.
What Problem Does This Paper Address?
Cancer cells often rely on uncontrolled proliferation, driven by genes like MYC. CDK9, a key component of the transcription elongation factor P-TEFb, plays a crucial role in regulating gene expression, including MYC. Inhibiting CDK9 is a promising cancer therapy strategy, but existing inhibitors often lack selectivity, affecting other essential enzymes and leading to toxicity. Furthermore, the precise mechanisms by which CDK9 inhibition impacts gene expression, particularly the proto-oncogene MYC, were not fully understood. This paper addresses the need for a selective CDK9 inhibitor and investigates the complex regulatory network involving CDK9, MYC, and the bromodomain protein BRD4 in cancer cells.
Methods
The study employed a multi-pronged approach:
- Drug Development: A novel, highly selective CDK9 inhibitor, i-CDK9, was developed through lead optimization.
- Biochemical Assays: In vitro kinase assays (AlphaScreen, KINOMEscan) were used to assess i-CDK9's selectivity against various CDK family members and other kinases.
- Cellular Assays:
- Western Blotting: Used to detect protein levels and phosphorylation states (e.g., pSer2 Pol II, pThr775 SPT5, MYC, CDK9, BRD4, HEXIM1, cleaved PARP, MCL-1) in response to drug treatment.
- qRT-PCR: To quantify MYC mRNA levels.
- ChIP-qPCR: To examine the binding of proteins (BRD4, CDK9, Pol II, acetyl-H3/H4) to specific genomic loci, particularly the MYC locus.
- ChIP-seq: Genome-wide analysis of Pol II occupancy to assess its distribution and pausing.
- Microarray Analysis: To determine global gene expression changes upon i-CDK9 treatment.
- Co-immunoprecipitation: To study protein-protein interactions (e.g., CDK9 with HEXIM1 and BRD4).
- Cell Proliferation and Apoptosis Assays: Including Celltiter-Glo and Caspase 3/7 assays, and flow cytometry (propidium iodide staining) to evaluate the synergistic effects of drug combinations.
- Bioinformatics: Gene Set Enrichment Analysis (GSEA) was used to identify enriched biological pathways.
Datasets
- Microarray Data: Gene expression profiling of HeLa cells treated with i-CDK9 was generated and submitted to the NCBI GEO database (Accession no: GSE60952).
- ChIP-seq Data: Pol II occupancy profiling in HeLa cells treated with i-CDK9 was generated and submitted to the NCBI GEO database (Accession no: GSE60953).
- KINOMEscan Data: Selectivity profiling against a panel of over 400 kinases was performed by DiscoveRx.
Key Insights and Ideas
- Selective CDK9 Inhibition: The development of i-CDK9 represents a significant step towards targeted CDK9 inhibition, offering a more precise tool than previous broad-spectrum inhibitors.
- Unexpected MYC Induction: Instead of suppressing all gene expression, i-CDK9 paradoxically upregulates MYC and other primary response genes. This is a critical finding, as MYC is a potent oncogene.
- BRD4 as a Key Mediator: BRD4 acts as a crucial adaptor, capturing P-TEFb from its inactive 7SK snRNP complex and delivering it to target genes like MYC.
- BRD4 Enhances CDK9 Activity: BRD4 not only recruits P-TEFb but also enhances CDK9's catalytic activity and makes it more resistant to i-CDK9 inhibition.
- Compensatory Mechanism: The induction of MYC is a cellular survival strategy to compensate for the loss of CDK9 activity, ensuring the transcription of essential genes.
- Dual Targeting Strategy: The compensatory MYC induction means that inhibiting CDK9 alone is insufficient for potent anti-cancer effects. Simultaneous inhibition of both CDK9 and MYC (or BRD4) is required for synergistic growth arrest and apoptosis.
Key Results
- i-CDK9 is a potent and highly selective inhibitor of CDK9, with significantly lower activity against other CDKs compared to flavopiridol.
- i-CDK9 treatment causes genome-wide Pol II pausing at gene promoters, leading to reduced expression of most genes.
- However, MYC and other primary response genes show increased expression upon sustained i-CDK9 treatment.
- This MYC induction is dependent on BRD4 and its interaction with acetylated chromatin.
- i-CDK9 treatment leads to the release of P-TEFb from the 7SK snRNP complex and its association with BRD4.
- BRD4 binding to P-TEFb increases CDK9's catalytic activity and resistance to i-CDK9.
- Simultaneous inhibition of CDK9 (with i-CDK9) and MYC (with JQ1 or 10,058-F4) synergistically induces growth arrest and apoptosis in cancer cells.
Limitations and Future Work
- Off-target Effects: While i-CDK9 is highly selective, the authors acknowledge that even selective inhibitors can have off-target effects at high concentrations. This underscores the importance of combination therapies at lower, potentially less toxic doses.
- Mechanism of BRD4 PID: The precise molecular mechanism by which the BRD4 PID promotes CDK9 activity and resistance to inhibition remains to be fully elucidated.
- MYC's Broader Role: The study suggests MYC plays a critical role in globally controlling Pol II release from pausing, extending beyond its canonical E-box binding. Further investigation into this broader function is warranted.
- Combinatorial Therapy Potential: The findings strongly suggest that combining CDK9 inhibitors with MYC or BRD4 inhibitors could be a promising therapeutic strategy for various cancers, particularly those addicted to MYC. This opens avenues for preclinical and clinical development.
Summary updated